MSME (Udyam registered) Ministry of MSME
- Category
- Small (2023-24)
- Udyam number
- UDYAM-UP-28-0028606
Dycine Pharmaceuticals Limited - pharma in Noida, Uttar Pradesh, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹28.83 Cr
▲ 6% YoY
Net profit · FY 2025
₹65.36 Lakh
Net margin 2.3%
EBITDA · FY 2025
₹5.35 Cr
EBITDA margin 18.6%
Authorised capital
₹40 Cr
Registered with MCA
Paid-up capital
₹35.27 Cr
Issued & subscribed
Open charges
₹37.92 Cr
Satisfied ₹9.5 Cr
Company age
16 yrs
Est. 2010
Employees · EPFO
248
Provident fund records
About Dycine Pharmaceuticals Limited
Data last updated:
Dycine Pharmaceuticals Limited is a public limited company based in Noida, Uttar Pradesh, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 30 July 2010 and has been in existence for over 16 years.
The company is registered with the Registrar of Companies (ROC), Uttar Pradesh, under CIN U74992UP2010PLC041545. Its GSTIN is 09AADCD5319H1ZO (Uttar Pradesh). The company holds 6 GST registrations, of which 5 are active.
The company has an authorised share capital of ₹40 Cr and a paid-up capital of ₹35.27 Cr. It is led by directors including Rupesh Kumar Gupta and Alok Kumar Singh.
Its last annual general meeting (AGM) was held on 29 November 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Shop No. 381 Block III Ganga Shopping Complex Sector 29, Noida, Uttar Pradesh, India – 201302.
As per the financials filed for FY 2025, the company reported a revenue of ₹28.83 Cr, a growth of 6% compared to the previous year. For the same year it recorded a net profit of ₹65.36 Lakh (net margin 2.3%) and EBITDA of ₹5.35 Cr (EBITDA margin 18.6%). Revenue has declined at a compounded annual rate (CAGR) of 5% over three years and 2% over five years.
The company has about 248 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Dycine Pharma. As per MCA filings, the company has open charges of ₹37.92 Cr and satisfied charges of ₹9.5 Cr on record. Court records list 3 cases involving the company, including 3 filed against it; 1 case is pending.
Dycine Pharmaceuticals Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-UP-28-0028606). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website dycinepharma.com.
Company details
CIN U74992UP2010PLC041545
Registration Number 041545
Incorporation Date 30 July 2010
ROC Uttar Pradesh
Listing Status Unlisted
Company Status Active
Date of Last AGM 29 November 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
MSME Classification Small
Udyam Registration UDYAM-UP-28-0028606
Recognitions & Rankings of Dycine Pharmaceuticals
Contact details
Dycine Pharmaceuticals Limited's registered office is in Noida, Uttar Pradesh. Its website is dycinepharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressShop No. 381 Block III Ganga Shopping Complex Sector 29, Noida, Uttar Pradesh, India – 201302
- IndustryPharma, Pharmaceutical Retailers & Distributors
To see the full contact details of Dycine Pharmaceuticals Limited, buy the company report.
Comprehensive company report
Dycine Pharmaceuticals Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Dycine Pharmaceuticals operates one associated brand: Dycine Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Dycine Pharma is an emerging group focused on developing and marketing a range of healthcare products. | dycinepharma.com |
Business activity
The main business activity of Dycine Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Dycine Pharmaceuticals Limited, buy the company report.
Financials of Dycine Pharmaceuticals Limited
FY 2025 filings availableDycine Pharmaceuticals Limited reported revenue of ₹28.83 Cr (up 6% YoY) for FY 2025.
Revenue · FY 2025
₹28.83 Cr ▲ 6%
Net profit · FY 2025
₹65.36 Lakh margin 2.3%
EBITDA · FY 2025
₹5.35 Cr margin 18.6%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 6%
3 years · compounded
▲ 5%
5 years · compounded
▼ 2%
EBITDA CAGR growth
1 year
▲ 67%
3 years · compounded
▲ 31%
5 years · compounded
▲ 21%
Revenue rose 6% in the latest year, though over five years it has declined at a compounded annual rate (CAGR) of 2%. EBITDA rose 67% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹5.35 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹65.36 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 18.6% | ||||
| Net Profit Margin | 2.3% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Dycine Pharmaceuticals Limited, buy the company report.
Board of directors of Dycine Pharmaceuticals Limited
Dycine Pharmaceuticals has 5 directors on record. No former directors are listed.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Rupesh Kumar Gupta | Director | 30 Jul 2010 | 16 Years 2 Months | Current |
| Alok Kumar Singh Also directs: Dycine Herbal Private Limited | Director | 30 Jul 2010 | 16 Years 2 Months | Current |
| Sai Uttam Bahirat Patil | Director | 25 Sep 2024 | 2 Years 0 Months | Current |
| Piyush Kumar Singh | Director | 30 Jul 2010 | 16 Years 2 Months | Current |
| Abhishek Agrawal | Director | 25 Sep 2024 | 2 Years 0 Months | Current |
Peer comparison
Dycine Pharmaceuticals Limited is compared with the 6 companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Stantech Pharmaceuticals Private Limited | ₹28.91 Cr (FY 2024) | 17.0% | Mumbai, Maharashtra, India | |||
| Meenakshi Ayurvedic Private Limited | ₹28.88 Cr (FY 2025) | 20.0% | Delhi, India | |||
| Goel Vet Pharma Private Limited | ₹28.84 Cr (FY 2024) | -7.0% | Chittorgarh, Rajasthan, India | |||
| Dycine Pharmaceuticals Limitedthis company | ₹28.83 Cr (FY 2025) | ₹65.36 Lakh | 2.3% | 6.0% | 248 | Noida, Uttar Pradesh, India |
| Perdaman Pharmaceuticals Private Limited | ₹28.76 Cr (FY 2025) | 4.0% | New Delhi, Delhi, India | |||
| Mediwest Life Care Private Limited | ₹28.7 Cr (FY 2024) | 83.0% | New Delhi, Delhi, India | |||
| Omni Lifesciences Private Limited | ₹28.68 Cr (FY 2025) | 14.0% | Vadodara, Gujarat, India |
To see the full peer comparison of Dycine Pharmaceuticals Limited, buy the company report.
Auditor
Dycine Pharmaceuticals Limited is audited by DSSM & ASSOCIATES LLP for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| DSSM & ASSOCIATES LLP | FY 2024 | C400024 |
Shareholding
The shareholding of Dycine Pharmaceuticals Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Dycine Pharmaceuticals Limited, buy the company report.
Charges & borrowings
Open charges
₹37.92 Cr
Satisfied charges
₹9.5 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 16 Jun 2026 | 101352390 | Hdfc Bank Limited | ₹1.68 Cr | Open | |
| 16 Mar 2026 | 101289070 | Hdfc Bank Limited | ₹53.48 Lakh | Open | |
| 28 Jan 2022 | 100559499 | Hdfc Bank Limited | ₹34.37 Cr | Open | |
| 28 Dec 2021 | 100537984 | Hdfc Bank Limited | ₹59.42 Lakh | Open | |
| 02 Nov 2018 | 100241539 | Others | ₹28.78 Lakh | Open |
To see the full charge records of Dycine Pharmaceuticals Limited, buy the company report.
Total charge records: 8 View all charges
Legal cases
Dycine Pharmaceuticals Limited has 3 court cases on record: 3 filed against it. 1 case is pending and 2 are disposed.
Total cases
3
Filed against the company
3
Pending
1
Disposed
2
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 3 | 3 | 1 |
Cases on record (2 of 3)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Lucknow, Uttar Pradesh | Criminal case | Filed against the company by State of Up | Pending |
| District court, Mathura, Uttar Pradesh | Criminal case | Filed against the company by State Government | Disposed |
To see the full case history of Dycine Pharmaceuticals Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Dycine Pharmaceuticals Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Dycine Pharmaceuticals Limited has a workforce of 248 employees on its EPFO records as of Jan 03, 2025, across 1 active EPFO establishment.
Employee count
248
Active EPFO establishments
1
Employee growth
22.77%
GST
Dycine Pharmaceuticals has 6 GST registrations: 5 active and 1 cancelled or inactive. The first 4 active GSTINs are listed below.
Total GSTINs
6
Active
5
Cancelled / inactive
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 09AADCD5319H1ZO | Uttar Pradesh | Active | 01 Jul 2017 |
| 22AADCD5319H1Z0 | Chattisgarh | Active | 28 Mar 2018 |
| 05AADCD5319H1ZW | Uttarakhand | Active | 01 Apr 2018 |
| 23AADCD5319H1ZY | Madhya Pradesh | Active | 04 Sep 2019 |
To see the full GST registrations and return filing status of Dycine Pharmaceuticals Limited, buy the company report.
Recent activity
Dycine Pharmaceuticals Limited has 5 board changes on record since 2010: 5 appointments. The latest: Abhishek Agrawal was appointed as Director on 25 Sep 2024.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 1.68 Cr with Charge ID 101352390 was registered on 16 Jun 2026.
Charges
A charge with Hdfc Bank Limited of Rs. 34.37 Cr registered on 28 Jan 2022 with Charge ID 100559499 was modified on 19 Mar 2026.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.53 Cr with Charge ID 101289070 was registered on 16 Mar 2026.
AGM
Dycine Pharmaceuticals Limited last Annual general meeting of members was held on 29 Nov 2025 as per latest MCA records.
Filing
Dycine Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Uttar Pradesh Ii.
Appointed
Abhishek Agrawal was appointed as Director.
Appointed
Sai Uttam Bahirat Patil was appointed as Director.
Charges
A charge registered on 26 Mar 2021 via Charge ID 100459776 with Sidbi was fully satisfied on 07 Apr 2022.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 34.37 Cr with Charge ID 100559499 was registered on 28 Jan 2022.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.59 Cr with Charge ID 100537984 was registered on 28 Dec 2021.
Charges
A charge with Sidbi amounted to Rs. 9.50 Cr with Charge ID 100459776 was registered on 26 Mar 2021.
Charges
A charge with Others amounted to Rs. 0.29 Cr with Charge ID 100241539 was registered on 02 Nov 2018.
6 earlier events are in the company report.
Frequently asked questions
Dycine Pharmaceuticals is an active public limited company based in Noida, Uttar Pradesh, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 30 July 2010 (16+ years old) and is registered under CIN U74992UP2010PLC041545.
Dycine Pharmaceuticals has 5 current directors:
- Rupesh Kumar Gupta - Director
- Alok Kumar Singh - Director
- Sai Uttam Bahirat Patil - Director
- Piyush Kumar Singh - Director
- Abhishek Agrawal - Director
The latest financial statements of Dycine Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 29 November 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Dycine Pharmaceuticals is 09AADCD5319H1ZO, registered in Uttar Pradesh. The company has 6 GST registrations in all, of which 5 are active and 1 is cancelled or inactive. Other active GSTINs include 22AADCD5319H1Z0 (Chattisgarh), 05AADCD5319H1ZW (Uttarakhand), 23AADCD5319H1ZY (Madhya Pradesh).
The CIN (Corporate Identification Number) of Dycine Pharmaceuticals is U74992UP2010PLC041545. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Dycine Pharmaceuticals has 3 court cases on record: 3 filed against it. 1 is pending.
Dycine Pharmaceuticals was incorporated on 30 July 2010, making it 16+ years old. It is registered with the Registrar of Companies, Uttar Pradesh.
The peers of Dycine Pharmaceuticals by revenue are Stantech Pharmaceuticals Private Limited, Meenakshi Ayurvedic Private Limited, Goel Vet Pharma Private Limited, Perdaman Pharmaceuticals Private Limited, Mediwest Life Care Private Limited and 1 more, all in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals), with the same principal business activity (wholesale trading).
Abhishek Agrawal was appointed as Director on 25 Sep 2024. Sai Uttam Bahirat Patil was appointed as Director on 25 Sep 2024. Alok Kumar Singh was appointed as Director on 30 Jul 2010. Dycine Pharmaceuticals has 5 board changes on record in total.
Yes, Dycine Pharmaceuticals is registered as a small enterprise under Udyam registration (number: UDYAM-UP-28-0028606).
Dycine Pharmaceuticals can be reached through the website dycinepharma.com. Its registered office is in Noida, Uttar Pradesh, India.